Position in EXEL
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$748,300
+$164,310 QoQ
Shares Held
13,753
+1.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#374
of 751 holders
Holding Since
Jun 2025
4 quarters on record
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KESTRA PRIVATE WEALTH SERVICES, LLC holds $13,960,546 across 25 Biotechnology names. EXEL ranks #4 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,539 | $5,235,037 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
50,588 | $2,379,659 | |
| 3 | INCY |
Incyte Corp
|
8,684 | $984,418 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
13,753 | $748,300 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
944 | $588,621 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
10,555 | $575,669 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
13,064 | $509,626 | |
| 8 | RPRX |
Royalty Pharma plc
|
7,881 | $441,887 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $748,300 | 13,753 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $583,990 | 13,616 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $616,512 | 14,066 | Shares | Sole | 2026-01-29 | |
| 2025-06-30 | $213,082 | 4,834 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||